Roivant to present Phase 2 mosliciguat data at ERS Congress Sept. 8

September 6, 2026 1:00 AM

Roivant Sciences (Nasdaq: ROIV) and its subsidiary Pulmovant announced that topline results from the Phase 2 PHocus study of mosliciguat ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found